A randomized, open-label, international, multi-center, Phase 2 study of Bortezomib Subcutaneous versus Intravenous administration in combination with cyclophosphamide and dexamethasone regimen in newly diagnosed patients with Multiple Myeloma.

Trial Profile

A randomized, open-label, international, multi-center, Phase 2 study of Bortezomib Subcutaneous versus Intravenous administration in combination with cyclophosphamide and dexamethasone regimen in newly diagnosed patients with Multiple Myeloma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Feb 2016 Status changed from not yet recruiting to recruiting.
    • 12 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top